Compare · ELMD vs LIVN
ELMD vs LIVN
Side-by-side comparison of Electromed Inc. (ELMD) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELMD and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $5.06B, about 26.8x ELMD ($189.1M).
- LIVN has been more active in the news (7 items in the past 4 weeks vs 6 for ELMD).
- LIVN has more recent analyst coverage (21 ratings vs 3 for ELMD).
- Company
- Electromed Inc.
- LivaNova PLC
- Price
- -
- -
- Market cap
- $189.1M
- $5.06B
- 1M return
- -
- +17.72%
- 1Y return
- -
- +70.76%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2011
- News (4w)
- 6
- 7
- Recent ratings
- 3
- 21
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest ELMD
- SEC Form S-8 filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Electromed, Inc. Delivers Continued Growth in Fiscal 2027 First Quarter
- Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026
- SEC Form DEF 14A filed by Electromed Inc.
- SEC Form DEFA14A filed by Electromed Inc.
- Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
- SEC Form 4 filed by Electromed Inc.
Latest LIVN
- Chief Financial Officer Shvartsburg Alex sold $227,275 worth of Ordinary Shares (2,500 units at $90.91) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 42,147 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
- LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
- Barclays initiated coverage on LivaNova with a new price target